Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C N Chan

Showing results (441-450 of 675) with videos related to

Pageof 68
Sort By:
The Lancet Regional Health. Western Pacific|October 13, 2025
Trends of lipid-lowering drug utilization, treatment intensity and LDL-C target attainment in adults with diabetes and non-dialysis chronic kidney disease in Hong KongYanting Huang, Aimin Yang, Mai Shi, et al.
Age and Ageing|October 9, 2025
A novel electronic-health-record based, machine-learning model to predict 1-year risk of fall hospitalisation in older adults: a Hong Kong territory-wide cohort and modelling studyAimin Yang, Mai Shi, Eric S H Lau, et al.
Diabetes Research and Clinical Practice|October 15, 2023
Comparison of beta-cell function between Hong Kong Chinese with young-onset type 2 diabetes and late-onset type 2 diabetesYingnan Fan, Baoqi Fan, Eric S H Lau, et al.
Diabetes Care|September 24, 2008
Additive interaction of hyperglycemia and albuminuria on risk of ischemic stroke in type 2 diabetes: Hong Kong Diabetes RegistryXilin Yang, Gary T C Ko, Wing Yee So, et al.
BMC Medicine|June 3, 2014
Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetesAlice P S Kong, Xilin Yang, Wing-Yee So, et al.
Diabetes, Obesity & Metabolism|April 16, 2011
A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetesA P S Kong, A Yamasaki, R Ozaki, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|June 12, 2010
Independent predictive roles of eotaxin Ala23Thr, paraoxonase 2 Ser311Cys and beta-adrenergic receptor Trp64Arg polymorphisms on cardiac disease in Type 2 Diabetes--an 8-year prospective cohort analysis of 1297 patientsY Wang, A O Y Luk, R C W Ma, et al.
Diabetes, Obesity & Metabolism|September 9, 2022
Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) registerLee-Ling Lim, Eric S H Lau, Johnny T K Cheung, et al.
Diabetes Care|February 12, 2014
Severe hypoglycemia identifies vulnerable patients with type 2 diabetes at risk for premature death and all-site cancer: the Hong Kong diabetes registryAlice P S Kong, Xilin Yang, Andrea Luk, et al.
BMC Endocrine Disorders|September 2, 2018
A proof-of-concept study to evaluate the efficacy and safety of BTI320 on post-prandial hyperglycaemia in Chinese subjects with pre-diabetesAndrea O Y Luk, Benny C Y Zee, Marc Chong, et al.
Pageof 68

Showing results (441-450 of 675) with videos related to

Sort By:
Pageof 68
The Lancet Regional Health. Western Pacific|October 13, 2025
Trends of lipid-lowering drug utilization, treatment intensity and LDL-C target attainment in adults with diabetes and non-dialysis chronic kidney disease in Hong KongYanting Huang, Aimin Yang, Mai Shi, et al.
Age and Ageing|October 9, 2025
A novel electronic-health-record based, machine-learning model to predict 1-year risk of fall hospitalisation in older adults: a Hong Kong territory-wide cohort and modelling studyAimin Yang, Mai Shi, Eric S H Lau, et al.
Diabetes Research and Clinical Practice|October 15, 2023
Comparison of beta-cell function between Hong Kong Chinese with young-onset type 2 diabetes and late-onset type 2 diabetesYingnan Fan, Baoqi Fan, Eric S H Lau, et al.
Diabetes Care|September 24, 2008
Additive interaction of hyperglycemia and albuminuria on risk of ischemic stroke in type 2 diabetes: Hong Kong Diabetes RegistryXilin Yang, Gary T C Ko, Wing Yee So, et al.
BMC Medicine|June 3, 2014
Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetesAlice P S Kong, Xilin Yang, Wing-Yee So, et al.
Diabetes, Obesity & Metabolism|April 16, 2011
A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetesA P S Kong, A Yamasaki, R Ozaki, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|June 12, 2010
Independent predictive roles of eotaxin Ala23Thr, paraoxonase 2 Ser311Cys and beta-adrenergic receptor Trp64Arg polymorphisms on cardiac disease in Type 2 Diabetes--an 8-year prospective cohort analysis of 1297 patientsY Wang, A O Y Luk, R C W Ma, et al.
Diabetes, Obesity & Metabolism|September 9, 2022
Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) registerLee-Ling Lim, Eric S H Lau, Johnny T K Cheung, et al.
Diabetes Care|February 12, 2014
Severe hypoglycemia identifies vulnerable patients with type 2 diabetes at risk for premature death and all-site cancer: the Hong Kong diabetes registryAlice P S Kong, Xilin Yang, Andrea Luk, et al.
BMC Endocrine Disorders|September 2, 2018
A proof-of-concept study to evaluate the efficacy and safety of BTI320 on post-prandial hyperglycaemia in Chinese subjects with pre-diabetesAndrea O Y Luk, Benny C Y Zee, Marc Chong, et al.
Pageof 68